InvenireX Secures £2 Million Seed Funding to Advance Ultra-Sensitive DNA Detection Platform
InvenireX, a Newcastle-based biotechnology startup, has secured £2 million in seed funding to accelerate the development and commercialisation of its DNA nanotechnology platform designed to transform molecular detection across healthcare and life sciences. Founded in 2021 by Dr. Dan Todd, the company emerged from doctoral research at Newcastle University and has since focused on addressing long-standing limitations in how nucleic acids are detected and measured.
The seed round was led by DSW Ventures, a UK early-stage venture capital firm with a focus on supporting technology companies outside of traditional innovation hubs. The round also included participation from XTX Ventures and Cambridge Technology Capital, alongside a group of experienced angel investors from the biotechnology and life sciences sectors. In addition to private capital, InvenireX also received non-dilutive grant support from Innovate UK, further strengthening the company’s financial position as it enters its next phase of growth.
This latest funding builds on earlier momentum. In March 2024, InvenireX raised £500,000 in an initial investment round, also led by DSW Ventures with backing from XTX Ventures. That earlier funding supported the refinement of the company’s core technology, early prototype development, and engagement with potential commercial partners. The new £2 million injection significantly expands InvenireX’s runway and enables a broader push toward scaling operations.
InvenireX’s technology centres on proprietary DNA “nanites,” programmable nanostructures engineered to capture and identify specific genetic sequences with extreme precision. These nanites are combined with custom microfluidic chips and an AI-enabled reader, allowing for real-time detection and quantification of nucleic acids. The company positions its platform as an alternative to conventional molecular techniques that often require complex sample preparation and can lose critical biological information during processing.
According to the company, early testing has demonstrated performance gains that substantially exceed existing standards. InvenireX reports that its system has shown up to 200-fold greater sensitivity compared with quantitative PCR and around 60-fold improvement over digital PCR, while also reducing both testing time and cost by approximately half. Such gains could have wide-ranging implications for applications including early cancer detection, infectious disease diagnostics, vaccine manufacturing, and broader life sciences research.
The newly raised capital will be used to expand InvenireX’s multidisciplinary team, advance product development, and scale pilot programmes with industry partners. The company is also preparing for the commercial rollout of its flagship instrument, known as R.O.S.A.L.I.N.D., which is intended to enable ultra-early detection of diseases that leave even minimal nucleic acid traces.
Founder and chief executive Dr. Dan Todd has described the company’s ambition as enabling scientists and clinicians to detect diseases such as cancer, HIV, and sepsis far earlier than is currently possible. By improving sensitivity at very low concentrations, InvenireX aims to open new frontiers in preventative healthcare and biological discovery.
Investors involved in the round have highlighted both the technical strength of the platform and the broader opportunity to build a globally significant biotech company from the North East of England. Continued backing from returning investors reflects confidence in the company’s progress since its first raise and belief in its long-term commercial potential.
With strong investor support, public grant funding, and growing interest from potential customers, InvenireX is positioning itself as a notable emerging player in molecular diagnostics. As it moves toward wider commercial adoption, the company aims to play a role in reshaping how diseases are detected and monitored, potentially enabling earlier intervention and improved outcomes across healthcare and research worldwide.
